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Abstract
Diabetes in pregnancy is associated with adverse maternal
and neonatal outcomes. Due to variations in insulin
resistance throughout pregnancy there is a continuous
need to implement Medical Nutrition Therapy (MNT),
exercise and pharmacological treatments which have to be
escalated. Self-monitoring of blood glucose (SMBG) is
integral to the management of diabetes in pregnancy.
Proper implementation of SMBG in pregnant women with
diabetes requires patient education and understanding of
its applications and limitations. Real-time results enable
individuals to make informed daily self-care decisions
regarding diet, exercise, and insulin. Retrospective analysis
of SMBG data enables clinicians to develop individualized
care plans, informing decisions related to insulin initiation
and adjustment and the possible needs for interventions or
hospitalization to improve inadequate self-monitoring.
Keywords: Pregnancy, Diabetes Mellitus, Self-monitoring
of blood glucose, hyperglycaemia.
Introduction
The St.VincentDeclaration in 1989 in ameeting arrangedby
World Health Organization (WHO) and International
Diabetes Federation (IDF) highlighted in one of its clause in
the Five-year targets as "……Achieve a pregnancy outcome
in the diabetic woman that approximates that of the non-
diabetic woman…..".1 But as yet we are far from achieving
such an outcome globally. The troubling aspect is the
increasing incidence of Diabetes Mellitus in the young. The
IDF Atlas 2015 gave an estimate that 86,000 children under
15 years develop Type 1 diabetes Mellitus (T1DM) annually
worldwide.2 Interestingly the incidence of Type 2 Diabetes
Mellitus (T2DM) is increasing in children and adolescents in
some countries. Rising incidence/prevalence of Diabetes
Mellitus in young means that these individuals will be
starting their reproductive lives with Diabetes as a co-
morbid and more and more pregnancies will be
complicated by diabetes. In the year 2015, 20.9 million
(16.2%) live births were affected by hyperglycaemia in
pregnancy out of which 85.1% were due to Gestational
Diabetes and 7.4%and 7.5%were due to overt diabetes and
pre-existing diabetes respectively.2 The South-East Asian
region is facing the major brunt with 24.2% pregnancies
complicated by some form of hyperglycaemia.2 Sadly, the
vast majority (87.6%) of hyperglycaemia in pregnancy is
from low and middle-income countries where the access to
maternal care is already compromised.2
Pregnancies complicated by Hyperglycaemia whether it's
Gestational, Overt or Pre-existing T1DM or T2DM are
associated with significant maternal and foetal/neonatal
morbidity and mortality.3 However, with the discovery of
insulin and its safety for use in pregnancy and then in later
years the evidence on the safety of some oral anti-
hyperglycaemic agents in pregnancy resulted in improved
outcomes of such pregnancies. Anothermajor technological
advancement, however, is the availability of glucose meters
for personal use through which self-monitoring of blood
glucose (SMBG) helps the patient and the health care
provider in making treatment decisions and modifications.4
Need to self-monitor blood glucose during
pregnancy
Optimizing glycaemic control improves the maternal and
neonatal outcomes but achieving such tight control as
recommended for preconception and pregnancy are not
easy (Table).5 Achieving such targets are quite challenging
and if thewoman is at risk of frequent hypoglycaemic events
especially those with T1DM who often get hypoglycaemia
unawareness then the targets can be relaxed to a little
extent.4 Since the insulin physiology alters throughout
pregnancy there is a great need to modify pharmacological
treatments throughout pregnancy which is impossible
without dedicated SMBGs. In early pregnancy, there is insulin
sensitivity in T1DMs and some variability to this insulin
sensitivity which results in frequent modifications of insulin
doses.4 However, for most of Prediabetes, T2DMs and overt
DM of pregnancy will notice increasing insulin requirements
during pregnancy. The insulin resistance rises exceptionally
during the late second and third trimester of pregnancy and
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Table: Recommended glycemic targets in pre-conception period and during
pregnancy.
Timing Goal
mg/dl mmol/l
Fasting On awakening 60-90 3.3-5.0
Preprandial Before every meal 60-90 33.5.0
1-hour postprandial 1 hour after every meal 70-140 3.9-7.8
2-hour postprandial 2 hour after every meal 70-120 3.9-6.7
plateaus towards the end of third trimester necessitating
insulin dose adjustments accordingly based upon SMBG.4
Timing and frequency of Self-monitoring of
blood glucose
There is no "one size fit all" approach and the advice on
how and when to test in a particular pregnant woman has
to be individualized.6 To achieve a good metabolic control
in a pregnant woman with hyperglycaemia, the timing
and frequency of SBMG has to be tailored based upon
following factors:
 Diagnosis — whether the woman has Pre-existing
T1DM, Pre-existing T2DM, Overt Diabetes of pregnancy or
Gestational Diabetes Mellitus
 Stage of pregnancy — whether she is in her first, second
or third trimester of pregnancy.
Hypoglycaemiaawareness—whether she ishypoglycaemia
aware or unaware. Someone who has unawareness of
hypoglycaemiawill needmore frequent SMBG.
 Evidence of polyhydramnios and foetal macrosomia on
foetal growth scan — Postprandial monitoring is associated
withbetter glycaemic control and lower riskofpreeclampsia.7
However, if there is evidence of polyhydramnios and foetal
macrosomia on foetal growth scan despite an apparent
normal control based upon fasting and post-prandial
measurements then there is a need to increase the frequency
of SMBG to detect unusual hyperglycaemic peaks that are
leading to such problems in growth scan.
SMBGs in women with Pre-existing T2DM or
Overt diabetes of pregnancy
In early weeks of pregnancy, the high maternal blood
glucose increases the risk of miscarriages and congenital
malformations thus frequent SMBGs and insulin dose
adjustments are required. Ideally fasting, premeals and 1 or
2-h post meals glucose values should be obtained on daily
or alternate days and this data should be utilized to look for
adherence to medical nutrition therapy and to make
necessary and frequent insulin dose adjustments. The
frequency of testing can be reduced in early second
trimester but has to be increased again later since the
hyperglycemia during the late second trimester and third
trimester directly leads to fetal hyperinsulinemia that leads
tomacrosomia and neonatal hypoglycemia.8 The increasing
insulin resistance of pregnancy at this stage warrants
frequent insulin dose adjustments based on SMBGs.
Another problem could be severe hypoglycemia that is
highlighted in a studyon27pregnantwomenwithT2DM. In
the year before pregnancy only 0.1 event/patient-year were
reportedbut duringpregnancy 0.9 events patient-yearwere
reportedwith frequencies of 0.5, 0.8 and 1.2 events/patient-
year in 1st, 2nd and 3rd trimester respectively.9 Patient
education and SMBGs with tailored treatments can lessen
the risk of these hypoglycemic episodes.
SMBGs in women with Pre-existing T1DM
Due to the changes in insulin sensitivity in the 1st trimester of
pregnancy and since this is the crucial period of
organogenesis, the need for frequent SMBGs cannot be over-
emphasized. Women with T1DM in their 1st trimester are at
risk of frequent hypoglycaemia including severe
hypoglycaemia that can lead tohypoglycaemiaunawareness.
In 108 pregnant T1DM women; severe hypoglycaemia
occurred in 45% of women with the frequencies of 5.3, 2.4
and 0.5 events per patient-year in 1st, 2nd and 3rd trimester
of pregnancy respectively.10 In the same cohort of women,
mild hypoglycaemia occurred by 5.5 events/patient-week in
early pregnancy and decreased throughout pregnancy.10
Predictors of severe hypoglycaemia were history of severe
hypoglycaemia and impaired awareness.10 Pregnant women
withT1DMshould thus be testing their bloodglucose at least
6-10 times daily including premeals, post prandials, bedtime,
early morning i.e. 3-4 am and modify their MNT and insulin
doses according to the advice of their physician.11
SMBGs in women with Gestational Diabetes
Mellitus
Women with GDM can perform their fasting glucose and 1
or 2 hour post prandial glucose. Initially when they are on
MNT and exercise alone the frequency of testing can be
reduced to alternate days or every 3rd day.12 Once they are
started on pharmacological treatment then they need to
test ondaily basis especially in the later part of 2nd trimester
and 3rd trimester. Insulin treated patients need more
frequent SMBGs as compared to oral antihyperglycaemic
agent treated women. Patients who are well controlled can
reduce their frequency of testing to alternate day.
Translating the SMBG data for treatment
decisions and adjustments
It is important to differentiate between checking blood
glucose vs.monitoring as SMBG. A pregnant patient cannot
monitor their glucose without checking but unfortunately
patients often check their glucosewithout trulymonitoring
it which implies that theymust understandwhat to dowith
the glucose reading and what measures to take. The
pregnant diabetic woman is very committed, motivated
and compliant and the health care professional has to
educate her sufficiently to gain the maximum benefit of
these positive attributes to achieve better neonatal and
maternal outcomes. This data helps them make changes in
their MNT and exercise. Pregnant women can be educated
to self-adjust their insulin doses according to their SMBG
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logs and this self-adjustment of insulin can be checked for
their appropriateness on clinical visits. Similarly these logs
help the physician in counseling the patient about the
effect of MNT, exercise and relationship of her glucose
values to her basal or bolus insulin. This data is extremely
useful in making dose escalations in pharmacological
treatments as the pregnancy progresses.
Dynamics of Glucose meters
There are several kinds of glucosemeters available that vary
in terms of different characteristics like volume of blood
sample, size, speed of testing, memory capacity, type of
technology applied, costs, need for a code and type of strips
used.6 Since the introductionof glucosemeters in 1970s, the
accuracy (how closely the measured value is to the actual
value) and precision (the ability to obtain highly
reproducible results) have been steadily improving.8 The
hazards of incorrect readings will be suboptimal treatment
decisions including improper adjustments in medication
dosage potentially increasing the frequency of both
hypoglycaemia and hyperglycaemia. All this can result in a
huge impact on the pregnant woman and her baby. Thus a
pregnant patient requires the highest accuracy in glucose
monitoring especially in those who have hypoglycaemia
unawareness as well. If the meter result is ±5% compared to
laboratory values, is considered the most accurate while ±
10% and ±15% are considered more accurate and accurate
respectively.8 However, even themost accuratemeter today
has only 63% acceptable values in the 5% accuracy range.8
Thus, it can be difficult for the physicians and patients to
assess the accuracy of blood glucose monitoring systems
and SMBG errors are poorly understood by patients and
their providers. The physician can help identify the source of
errors that can result in inaccurate results and can help
prevent and correct such errors.
Overcoming barriers to self-monitoring of
blood glucose during pregnancy
Patient education remains the key to the success of SMBG
during pregnancy. They need to be educated about the
importance of SMBGs which help in making therapeutic
decisions and dose adjustments that has a primary role on
reducing the complications during and after pregnancy.
The patient must be properly educated about all the
aspect of meter use i.e. how to code the meter, wash her
hands prior to testing and applying correct amount of
blood to the test strip.6 They need to be educated about
the proper storage and disposal of test strips, the fact that
they should use test strips before expiration. If the strips
are subjected to extremes of temperature and humidity
then these have to be disposed of.6 Similarly, the
education should address her fears of inconvenience and
pain due to lancet prick, social stigmas of testing in public
places. They should be educated about keeping their logs
of SMBGs, food, and doses of their insulin on specific
charts (Figure-1).
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Figure-1: Glucose monitoring chart & diet diary.
Continuous Glucose Monitoring systems (CGM)
Real-time CGM generates a detailed profile of glucose
excursions that can be helpful when making decisions
regarding self-care and treatment planning.8 A secondary
analysis of two European randomized controlled trials of
continuous glucose monitoring in 89 patients with T1DM
and 28 patients with T2DM showed that a higher mean
glucose level (126 compared with 120 mg/dL) in the
second and third trimesters (117 compared with 115
mg/dL) occurred in pregnancies with Large for
gestational age (LGA) neonates compared with those with
non-LGA neonates.13 This analysis was able to pick some
specific patterns of hyperglycaemia which could be target
to additional insulin coverage and adjustments.
CGM can identify many episodes of hypo- and
hyperglycaemia that would go undetected by SMBG. CGM
appears superior to SMBG in this regard, but it remains to
be seenwhether CGM improves pregnancy outcomes and
cost is a major concern in middle and low socioeconomic
countries.8
The expert suggestion about CGM is to use it during
pregnancy complicated by either gestational or pre-
existing diabetes Mellitus when SMBGs are not sufficient
to assess glycaemic control including both
hyperglycaemia and hypoglycaemia.11
The Future
Different research groups have developed interactive,
smartphone- based, remote blood glucose monitoring
systems and have demonstrated their convenience and
acceptability to women with GDM.14 Clinical and
economic outcomes of such systems are currently under
investigation.
Conclusion
Insulin use and SMBGs have revolutionized management
of a pregnancy complicated by diabetes. Achieving
adequate glycaemic control is the key to improve
maternal and neonatal outcomes. The most important
step towards a tight glycaemic control in pregnancy is
patient adherence to SMBG. A pregnant woman is the
most compliant and motivated patient amongst all the
patients with diabetes and for a short period of
pregnancy a shared care involving physicians, diabetes
educators and nutritionists with the patient at the center
is paramount to a successful outcome. With proper
education of the pregnant woman, SMBG data can be
utilized in real-time by the patient herself to make
treatment and lifestyle adjustment and in retrospect by
her physician to individualize care and make necessary
therapeutic decisions.
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